Caremark Supports Florida Attorney General's Motion to Intervene in Qui Tam Lawsuit

Business Wire, June 17, 2004

NASHVILLE, Tenn. -- Caremark Rx, Inc. (NYSE:CMX) said that it supports a motion filed today by the Florida Attorney General to intervene in a Qui Tam lawsuit filed against the company. After a review of the relevant facts in the Qui Tam lawsuit filed against Caremark in 2003 by relators Michael Fowler and Peppi Fowler, the State of Florida Department of Legal Affairs (the Department), headed by the Florida Attorney General, today filed the motion to intervene.

Caremark has strenuously refuted the allegations brought against the company by the relators and sought the Florida Attorney General's intervention. In the motion, the Department indicated that the State of Florida had received information arising from the relators' employment relationship with Caremark which causes the Department to believe that it, and not the relators, should direct the litigation of this matter on behalf of the State of Florida. The Department also indicated that there is a strong possibility that one or more of the relators and the Department could soon be adversaries in an administrative proceeding involving professional regulation.

Immediately following the filing of the Department's motion, Caremark today filed a separate motion to stay all discovery in this case on the basis that it would be inappropriate for the relators to continue participating in discovery until the court has ruled on the Department's motion to intervene.

Filings containing these specific motions and other information about this case can be found once they are posted to the Leon County Florida Court of Clerks website at http://cvweb.clerk.leon.fl.us/.> About Caremark Rx, Inc.

Caremark Rx, Inc. is a leading pharmaceutical services company, providing through its affiliates comprehensive drug benefit services to over 2,000 health plan sponsors and their plan participants throughout the U.S. Caremark's clients include corporate health plans, managed care organizations, insurance companies, unions, government agencies and other funded benefit plans. The company operates a national retail pharmacy network with over 55,000 participating pharmacies, seven mail service pharmacies, the industry's only FDA-regulated repackaging plant and 21 specialty pharmacies for delivery of advanced medications to individuals with chronic or genetic diseases and disorders.

Safe Harbor Statement

This press release contains statements that constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations of management. There are a number of risks and uncertainties that could cause actual results to differ materially from the expectations of management. You are encouraged to consult the filings which Caremark Rx, Inc. makes with the Securities and Exchange Commission under both the Securities Act of 1933 and the Securities Exchange Act of 1934 for more information concerning such risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this press release.

Additional information about Caremark Rx is available on the World Wide Web at www.caremarkrx.com.